Clinical Adverse Events Associated with Sodium–Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals

A hypothesis for why sodium glucose co‐transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection

(2020) Michael Fralick et al.   DIABETES OBESITY & METABOLISM

Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials

(2020) Jiali Liu et al.   DIABETES OBESITY & METABOLISM

Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials

(2020) Satoshi Miyashita et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors

(2020) Nicola Fleming et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists

(2020) Tanya Wilcox et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

(2020) Antonios Douros et al.   ANNALS OF INTERNAL MEDICINE

Sodium‐glucose cotransporter‐2 ( SGLT ‐2) inhibitors and major adverse limb events: a trial‐level meta‐analysis including 51,713 individuals

(2020) Chen‐Yu Huang et al.   DIABETES OBESITY & METABOLISM

Discontinuation rate and reason for discontinuation after sodium‐glucose cotransporter 2 inhibitor prescription in real clinical practice

(2020) Hyunah Kim et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis

(2020) James Heyward et al.   PLoS One

Prevalence and Clinical Characteristics of Adults Presenting With Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital

(2020) Alexa Clark et al.   Canadian Journal of Diabetes

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

(2020) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review

(2020) Adeboye Olakunle Bamgboye et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

(2020) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases

(2019) Lu Wang et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis

(2019) Jan Menne et al.   PLOS MEDICINE

SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials

(2018) Robert Puckrin et al.   ACTA DIABETOLOGICA

Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study

(2018) Young-Gun Kim et al.   DIABETES OBESITY & METABOLISM

Risk of Amputations Associated with SGLT2 Inhibitors Compared to DPP-4 Inhibitors: A Propensity-Matched Cohort Study

(2018) Sruthi Adimadhyam et al.   DIABETES OBESITY & METABOLISM

Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis

(2018) Xin‐Lin Zhang et al.   Journal of the American Heart Association

Acute renal outcomes with SGLT-2 inhibitors - real world data analysis

(2018) Avivit Cahn et al.   DIABETES OBESITY & METABOLISM

Comparative risk of genital infections associated with SGLT2 inhibitors: A real-world retrospective cohort study

(2018) Chintan V. Dave et al.   DIABETES OBESITY & METABOLISM

Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis

(2018) Sruthi Adimadhyam et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

(2018) Peter Ueda et al.   BMJ-British Medical Journal

SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature

(2017) Kelly R. Burke et al.   PHARMACOTHERAPY

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis

(2017) Jiali Liu et al.   Scientific Reports

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE